May 1, 2011
Bookmark and Share  



My name is Lucinda K. Porter. I am a nurse, writer, educator and hepatitis C patient. I've been with the Hepatitis C Support Project pretty much since its inception. In addition to my "HealthWise" column, I recently started writing "HCV Snapshots" (this month it is co-authored with Alan Franciscus). I also write and co-author many of the fact sheets and guides.

This month's issue of the HCV Advocate is especially exciting, especially the news from the annual meeting of the European Association for the Study of the Liver. Spoiler Alert: Excellent treatments for hepatitis C are on the horizon and if you haven't gotten excited yet, just wait.

Best of Health,
Lucinda K. Porter, RN


1. HCV Advocate Newsletter: May 2011

In This Issue:


2. HBV Journal Review: May 2011

  • Experts Highlight Under-Treatment of Hepatitis B in the U.S.
  • Only 61.7% of U.S. Health Care Workers Immunized Against Hepatitis B
  • Surface Antibodies May Not Completely Eradicate Hepatitis B

and more..........................


3. Action Alert: Urge Your Members of Congress to Attend Historic Viral Hepatitis Congressional Briefing — May 12, 2001. Click Here


***This just in: FDA Panel Backs 2 Hepatitis C Drugs. Both telaprevir and boceprevir (Victrelis™) received unanimous approval from the FDA committee. Final decision to be made before the end of May, 2011


Don’t forget to keep checking out our blog for more about the most recent news stories.



Alan Franciscus
Executive Director, Hepatitis C Support Project
Editor-in-Chief, HCV Advocate
Editor-in-Chief, HBV Advocate


**Questions and Comments: Questions and/or comments can be directed to

**To receive the eblast in your email inbox simply send an e-mail to: with nothing in the subject line and the following in the message body: subscribe emailalert. Make sure your email address is all lower case.